In two phase 3 trials of adults with COPD and prior exacerbations on inhaled therapy, add-on tozorakimab (anti-IL-33) cut moderate or severe exacerbations in former smokers vs placebo (rate ratios 0.71 and 0.66); overall population results were similar.
RCTn = 1,750
Sciurba et al. Tozorakimab to Prevent COPD Exacerbations